Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL)

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 857-861

  Ceesay, M Mansour ^a   Matutes, Estella ^b   Taylor, Graham P ^c   Fields, Paul ^d   Cavenagh, Jamie ^e   Simpson, Sylwia ^a   Ho, Aloysius ^a   Devereux, Stephen ^a   Mufti, Ghulam J ^a   Pagliuca, Antonio ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Adult T cell leukaemia lymphoma; Anti CD25 antibodies; HTLV 1

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB; DOXORUBICIN; HYDROCORTISONE; INTERFERON; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ARACHNOIDITIS; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONFUSION; DEPRESSION; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EVENT FREE SURVIVAL; FACIAL NERVE PARALYSIS; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HALLUCINATION; HEPATOSPLENOMEGALY; HERPES ZOSTER; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HYPERCALCEMIA; HYPOTENSION; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; LUNG TOXICITY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; LYMPHOCYTOSIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIC SEPSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SEPSIS; SKIN DEFECT; SKIN TOXICITY; SURVIVAL TIME; T CELL LEUKEMIA; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS CARCINOGENESIS; VIRUS LOAD; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84862315406     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.12.004     Document Type: Article

References (28)

1. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77:7415-7419.
2. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
3. Hinuma Y., Nagata K., Hanaoka M., et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981, 78:6476-6480.
4. Kaplan J.E., Khabbaz R.F. The epidemiology of human T-lymphotropic virus types I and II. Rev Med Virol 1993, 3:137-148.
5. Catovsky D., Greaves M.F., Rose M., et al. Adult T-cell lymphoma-leukaemia in Blacks from the West Indies. Lancet 1982, 1:639-643.
6. Franchini G. Disease association, genetics, and biology of human T-cell lymphotropic virus types I and II. American society of hematology 2000, 409-412. Education Program Book, San Francisco, CA. G. Franchini, R.F. Ambinder, M. Barry (Eds.).
7. Murphy E.L., Hanchard B., Figueroa J.P., et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989, 43:250-253.
8. Shimamoto Y., Suga K., Nishimura J., Nawata H., Yamaguchi M. Major prognostic factors of Japanese patients with lymphoma-type adult T-cell leukemia. Am J Hematol 1990, 35:232-237.
9. Shimamoto Y., Suga K., Shimojo M., Nishimura J., Nawata H., Yamagughi M. Comparison of CHOP versus VEPA therapy in patients with lymphoma type of adult T-cell leukemia. Leuk Lymphoma 1990, 2:335-340.
10. Taguchi H., Kinoshita K.I., Takatsuki K., et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:182-186.
11. Shimoyama M., Ota K., Kikuchi M., et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988, 6:128-141.
12. Bazarbachi A., Suarez F., Fields P., Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood 2011.
13. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-1987). Br J Haematol 1991, 79:428-437.
14. Uchiyama T., Hori T., Tsudo M., et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest 1985, 76:446-453.
15. Araki K., Harada K., Nakamoto K., Shiroma M., Miyakuni T. Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers. Clin Exp Immunol 2000, 119:259-263.
16. Kamihira S., Atogami S., Sohda H., Momita S., Yamada Y., Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994, 73:2753-2758.
17. Waldmann T.A., White J.D., Carrasquillo J.A., et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995, 86:4063-4075.
18. Waldmann T.A., White J.D., Goldman C.K., et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993, 82:1701-1712.
19. Waldmann T.A., Goldman C., Top L., et al. The interleukin-2 receptor: a target for immunotherapy. Adv Exp Med Biol 1992, 323:57-66.
20. Zhang Z., Zhang M., Garmestani K., et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood 2006, 108:1007-1012.
21. Chen J., Zhang M., Ju W., Waldmann T.A. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009, 113:1287-1293.
22. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
23. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
24. Tobinai K. Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park) 2009, 23:1250-1256.
25. Morris J.C., Waldmann T.A. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000, 59(Suppl. 1):i109-i114.
26. Matutes E., Taylor G.P., Cavenagh J., et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001, 113:779-784.
27. Bazarbachi A., Plumelle Y., Carlos Ramos J., et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010, 28:4177-4183.
28. Hodson A., Crichton S., Montoto S., et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J Clin Oncol 2011, [Published online October 31, 2011]. 10.1200/JCO.2011.35.5578.